Rémy Duléry
@RemyDulery
Followers
2K
Following
12K
Media
460
Statuses
3K
MD, PhD in Hematology at Saint Antoine Hospital @Sorbonne_Univ_ @APHP, Paris. Currently @DanaFarber @HarvardMed in #RomeeLab #NKcells #CARTcell
Joined January 2016
RT @TheIACH: 🔥 𝘋𝘰𝘯’𝘵 𝘮𝘪𝘴𝘴 𝘰𝘶𝘳 𝘭𝘢𝘵𝘦𝘴𝘵 𝘗𝘰𝘴𝘵-𝘈𝘚𝘊𝘖/𝘌𝘏𝘈 2025 𝘸𝘦𝘣𝘪𝘯𝘢𝘳!. 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗶𝗻 𝗟𝘆𝗺𝗽𝗵𝗼𝗺𝗮.🎙️𝘗𝘳𝘦𝘴𝘦𝘯𝘵𝘦𝘥 𝘣𝘺 𝘙𝘦́𝘮𝘺 𝘋𝘶𝘭𝘦́𝘳𝘺. 🎥𝘕𝘰𝘸 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘰𝘯….
0
5
0
RT @TheIACH: 📢 𝗪𝗲 𝗮𝗿𝗲 𝗟𝗜𝗩𝗘. 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗶𝗻 𝗹𝘆𝗺𝗽𝗵𝗼𝗺𝗮: 𝘂𝗽𝗱𝗮𝘁𝗲 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗰𝗼𝗻𝗴𝗿𝗲𝘀𝘀𝗲𝘀. 🆓 𝗙𝗿𝗲𝗲 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗵𝗲𝗿𝗲 ⤵️..
0
5
0
RT @lymphomahub: CONGRESS | #18ICML | PRESENTATION.Ali Bazarbachi discusses an analysis from the EBMT Lymphoma Working Party of outcomes fo….
0
9
0
RT @NGazeau14: Very happy to share our work on therapy-related myeloid neoplasms (t-MN) post-CD19 CAR T-cell therapy, published in @Leukemi….
nature.com
Leukemia - Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
0
9
0
Happy to participate to the 15th Forum for Cellular and Humoral Immunotherapy today at 4pm CET. I will discuss the risks of secondary malignancy after #CARTcell therapy. Feel free to register👉
0
0
1
RT @RShouval: 🚨 Check out our new grading system for thrombocytopenia (#T_ICAHT) after #CART @BloodJournal .Led by….
ashpublications.org
Key PointsBased on duration and timing of thrombocytopenia, we introduce T-ICAHT as a novel grading that expands on the existing N-ICAHT system.Severe (gra
0
5
0
Thank you @VJHemOnc for giving me the opportunity to discuss the findings of our recent publication in @NatureMedicine: #CARTcell #EBMT25 @LysaLymphoma.
nature.com
Nature Medicine - This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France...
Is there cause for concern regarding the development of T-cell malignancy after #CARTCell therapy? Do the benefits of the treatment outweigh the risks? 💉🩸. Find out in our interview from #EBMT25 with @RemyDulery (@DanaFarber):. 🎥 #ImmunoOnc @TheEBMT.
0
2
15
RT @Harvard: “No government—regardless of which party is in power—should dictate what private universities can teach, whom they can admit….
harvard.edu
No government—regardless of which party is in power—should dictate what private universities can teach, whom they can admit and hire, and which areas of study and inquiry they can pursue
0
30K
0
RT @romeerizwan: Excited to share our review on CAR arming of the innate immune cells. Engineering innate immune cells for cancer immunothe….
nature.com
Nature Biotechnology - The unique attributes of innate immune cells position them as attractive candidates for cancer immunotherapy, with engineering strategies to enhance their antitumor...
0
22
0
RT @lab_rezvani: Please check out our paper published in @NatureMedicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in….
0
52
0
RT @bchouster: Démagogie politique qui va réduire encore plus l’offre de soins et de façon injuste envers les étudiants en médecine. Ne lâc….
0
1
0
RT @ProfChrisPFox: Thank you… it was a pleasure to discuss an important question with a high quality opponent and an expert audience! @TheE….
0
1
0
Outstanding talk by @romeerizwan on harnessing innate NK cell memory in high-risk AML/MDS, highlighting promising clinical trials results and future directions. #EBMT25
0
1
14
Honored to present our latest #RomeeLab research on engineering IL-12-secreting CAR NK cells to target high-risk AML—demonstrating feasibility, safety, and efficacy. What a pleasure to be at #EBMT25 in Florence! 🇮🇹🌞. @romeerizwan @TheEBMT
0
2
18
RT @AML_Hub: CONGRESS | #EBMT25 @TheEBMT | PRESENTATION.@RadiciVera, @unibs_official, presents interim results from the phase II FT14 study….
0
6
0
RT @TheEBMT: Congratulations to the 2025 Jon J. van Rood Award winners Janaki Manoja Vinnakota (pictured) and Nicoletta Cieri! 👏. Read the….
0
6
0
RT @JACIE_EBMT: #EBMT25 The JACIE team is here in Florence! 🌍Visit our booth to get updates on the latest JACIE developments, meet our memb….
0
5
0